Mantle D, Falkous G, Ishiura S, Perry R H, Perry E K
Department of Neurochemistry, Newcastle General Hospital, Newcastle upon Tyne, UK.
J Neurol Sci. 1995 Jul;131(1):65-70. doi: 10.1016/0022-510x(95)00035-z.
Recent evidence, based upon immunocytochemical and histochemical analysis of brain cortical tissue from alzheimer's disease patients, has suggested that altered activity and/or distribution of the lysosomal proteases cathepsins B and D may be implicated in the abnormal protein processing pathway resulting in formation of the neurotoxic amyloid A4 peptide, characteristic of this neurodegenerative disorder. We have therefore compared, via biochemical assay techniques using conventional or specially synthesised (corresponding to protein cleavage points of relevant to A4 peptide formation) fluorogenic substrates, the levels of activity of the lysosomal proteases cathepsins B, D, H and L, and dipeptidyl aminopeptidases I and II in frontal cortex (grey/white matter) from control and Alzheimer's disease patients. For comparative purposes, activity levels of the above enzymes were also determined in frontal cortex tissue from cases with Lewy body dementia and Parkinson's disease, and in caudate tissue from control and Huntington's disease cases. There was no significant difference in activity for any protease types in tissue from control cases and cases with Alzheimer's disease, Lewy body dementia or Parkinson's disease, with the exception of reduced dipeptidyl aminopeptidase II activity in Lewy body dementia and Parkinson's cases. We have therefore been unable to confirm a potential role for lysosomal cathepsins in the characteristic neurodegeneration associated with Alzheimer's disease; however the finding of significant increases in activity of dipeptidyl aminopeptidase II, cathepsin H and cathepsin D specifically in cases with Huntington's disease is of particular note. We therefore suggest the potential role of the latter enzymes in the pathogenesis of Huntington's disease requires further investigation.
最近,基于对阿尔茨海默病患者大脑皮质组织的免疫细胞化学和组织化学分析的证据表明,溶酶体蛋白酶组织蛋白酶B和D的活性改变和/或分布改变,可能与导致神经毒性淀粉样A4肽形成的异常蛋白质加工途径有关,而神经毒性淀粉样A4肽是这种神经退行性疾病的特征。因此,我们通过生化检测技术,使用传统的或特别合成的(对应于与A4肽形成相关的蛋白质切割点)荧光底物,比较了对照患者和阿尔茨海默病患者额叶皮质(灰质/白质)中溶酶体蛋白酶组织蛋白酶B、D、H和L以及二肽基氨基肽酶I和II的活性水平。为了进行比较,还测定了路易体痴呆和帕金森病患者额叶皮质组织以及对照和亨廷顿病患者尾状核组织中上述酶的活性水平。对照病例以及患有阿尔茨海默病、路易体痴呆或帕金森病的病例的组织中,任何蛋白酶类型的活性均无显著差异,但路易体痴呆和帕金森病病例中的二肽基氨基肽酶II活性降低除外。因此,我们无法证实溶酶体组织蛋白酶在与阿尔茨海默病相关的特征性神经退行性变中具有潜在作用;然而,特别值得注意的是,在亨廷顿病患者中,二肽基氨基肽酶II、组织蛋白酶H和组织蛋白酶D的活性显著增加。因此,我们认为后一种酶在亨廷顿病发病机制中的潜在作用需要进一步研究。